(3) Management of the hypertensive patient

Pharmaceutical Journal

Volumn 263, Issue 7062, 1999, Pages 383-386

  Spencer, Charles ^a   Lip, Gregory ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; SODIUM;

AMBULATORY MONITORING; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG CHOICE; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIFESTYLE; NEGRO; PATIENT CARE; PATIENT MONITORING; PERIPHERAL VASCULAR DISEASE; PREGNANCY; RENOVASCULAR HYPERTENSION; SHORT SURVEY; SODIUM INTAKE; WEIGHT REDUCTION; WHITE COAT HYPERTENSION;

EID: 0040218682     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Watson RDS, Lumb R, Young MA, Stallard TJ, Davies P, Littler WA. Variation in cuff blood pressure in untreated outpatients with mild hypertension J Hypertens 1987;207:11.
2. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Porcellati C. White coat hypertension. Lancet 1996;348:1443.
3. Hingorani A, Vallance P. A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ 1999;318:101.
4. Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413.
5. Guidelines Subcommittee. 1999 World Health Organisation-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17:151.
6. Staessen J, Faggard R, Linjen P, Amery A. Body weight, sodium intake and blood pressure. Ibid 1989;7(Suppl 1):19.
7. Klatsky AL, Friedman GD, Siegelaub AB, Gerard MJ. Alcohol consumption and blood pressure. N Engl J Med 1977;296:1194.
8. Law MR, Frost CD, Wald NJ. III - analysis of data from trials of salt reduction. BMJ 1991;302:819.
9. He FJ, Markandu ND, Sagnella GA, MacGregor GA. Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 1998;32:820.
10. Shaper AG, Wannamethee G, Walker M. Physical activity hypertension and risk of heart attack in men without evidence of ischaemic heart disease. J Hum Hypertens 1994;8:3.
11. Chaturverdi N, Sjolie A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on the progression of retinopathy in normotensive people with type I diabetes. Lancet 1998;351:28.
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the collaborative study group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456.
13. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJM. Effect of angiotensin converting enzyme inhibitor trandolopril on human diabetic neuropathy: randomised double blind controlled trial. Lancet 1998; 352:1978.
14. Garg R, Yusuf S, for the collaborative group on ACE inhibitor trials. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450.
15. Cleland JGF, McGowan J, Clark A. The evidence for ß-blockers in heart failure. BMJ 1999;7187:824.
16. SHEP co-operative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255.
17. Staessen JA, Faggard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH et al for the Systolic Hypertension - Europe (Syst-Eur) trial investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet 1997;360:757.
18. World Health Organisation-International Society of Hypertension blood pressure lowering trialists' collaboration. Protocol for prospective collaborative overviews of major randomised trials of blood pressure lowering treatments. J Hypertens 1998;16:127.
19. Beevers DG, Lip GYH. Does non-malignant essential hypertension cause renal damage? A clinician's view. J Hum Hypertens 1996;10:695.
20. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW et al for the modification of diet in renal disease study group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877.
21. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC et al for the modification of diet in renal disease study group. Hypertension 1997;29:641.
22. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. ß-blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991;303:1100.
23. Materson BJ. Lessons on the interaction of race and antihypertensive drugs from the VA co-operative study group on antihypertensive agents. Am J Hypertens 1995;8:91S.
24. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW for the West of Scotland coronary prevention study group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301.
25. Lip GYH, Beevers M, Beevers DG. The "Birmingham Hypertension Square" for the optimum choice of add in drugs in the management of resistant hypertension. J Hum Hypertens 1998;12:761.